Study On Oral Insulin Nano-Matrix Drug Delivery System
LI Song， ZHANG Hua， WANG Xue-qing， WANG Jian-cheng， ZHANG Xuan， ZHANG Qiang
Author information+
School of Pharmaceutical Sciences， Peking University， Beijing 100191， China
{{custom_zuoZheDiZhi}}
{{custom_authorNodes}}
{{custom_bio.content}}
{{custom_bio.content}}
{{custom_authorNodes}}
Collapse
History+
Received
Revised
Published
2012-01-01
2012-01-01
2011-10-05
Issue Date
2011-10-05
Abstract
OBJECTIVE To design and prepare a novel nano-matrix drug delivery system for the oral administration of insulin. METHODS Insulin was adsorbed onto mesoporous silica and then covered with Eudragit as protective agent. Formulation composition and proportion， particle size distribution， protection against enzymolysis， and in vivo hypoglycemia behavior were studied. RESULTS With an average diameter of （466±111） μm， the resulted particles presented protective function against enzymolysis in vitro， as well as significant hypoglycemia effect in Intraperitoneal Glucose Tolerance Tests (IPGTTs). CONCLUSION This nano-matrix drug delivery system can be applied to the oral administration of insulin.
LI Song;ZHNG Hu;WNG Xue-qing;WNG Jin-cheng;ZHNG Xun;ZHNG Qing.
Study On Oral Insulin Nano-Matrix Drug Delivery System[J]. Chinese Pharmaceutical Journal, 2011, 46(19): 1496-1499
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] LI Y， WANG Y Z， XIA L Z. Retrospective analysis on the antidiabetic in our hospital during 2006- 2008 [J]. Chin J New Drugs (中国新药杂志)， 2010， 19(12)： 1087-1090. [2] NATHAN D M， BUSE J B， DAVIDSON M B， et al. Management of hyperglycaemia in type 2 diabetes： a consensus algorithm for the initiation and adjustment of therapy [J]. Diabetologia， 2006， 49（8）： 1711-1721. [3] DAMG C H， REIS C P， MAINCENT P H， et al. Nanoparticle strategies for the oral delivery of insulin [J]. Exp Opin Drug Deliv， 2008， 5(1)： 1-24. [4] CHEN M M， FANG Y， GU H. The application of nano in oral insulin delivery [J]. J Jinggangshan Med Coll (井冈山医专学报)， 2004， 11(5)： 12-13. [5] ZHANG Q， DING J J， YE G Q， et al. In vitro release kinetics and hypoglycemia effect on diabetic rats after oral administration of insulin loaded nanoparticles [J]. Acta Pharm Sin (药学学报)， 1998， 33(2)： 152-156. [6] JAIN D， PANDA A K， MAJUMDAR D K. Eudragit S100 entrapped insulin microspheres for oral delivery [J]. AAPS Pharm Sci Tech， 2005， 6(1)： 100-107. [7] BAYAT A， LARIJANI B， AHMADIAN S， et al. Preparation and characterization of insulin nanoparticles using chitosan and its quaternized derivatives [J]. Nanomedicine： Nanotechnology Biology and Medicine， 2008， 4（2）： 115-120. [8] SARMENTO B， MARTINS S， FERREIRA D， et al. Oral insulin delivery by means of solid lipid nanoparticles [J]. Int J Nanomedi， 2007， 2(4)： 743-749. [9] SALONEN J， KAUKONEN A M， HIRVONEN J， et al. Mesoporous silicon in drug delivery applications [J]. J Pharm Sci， 2008， 97(2)： 632-653. [10] XUE J M， SHI M. PLGA/mesoporous silica hybrid structure for controlled drug release [J]. J Controlled Release， 2004， 98（2）： 209-217. [11] MANZANO M， AINA V， AREAN C O， et al. Studies on MCM-41 mesoporous silica for drug delivery： Effect of particle morphology and amine functionalization [J]. Chem Engineer J， 2008， 137（1）： 30-37. [12] KAUKONEN A M， LAITINEN L， SALONEN J， et al. Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles [J]. Eur J Pharm Biopharm， 2007， 66（3）： 348-356. [13] Ch. P (2005) VolⅡ(中国药典2005年版.二部) [S]. 2005： 623. [14] ZHANG Q， WANG J C， GUO Y L. pH-Sensitive solid pharmaceutical compasition for oral formulation and preparation method： CN， 200710121430.9 [P]. 2009-03-11.
PDF(1017 KB)
